Bansi Sanghvi, PhD’s Post

A new dual-amplification CRISPR/Cas biosensing method, Cas13a-12a, has been developed for ultrasensitive detection of miRNA-155, a potential biomarker for early disease diagnosis. This innovative approach leverages the specific nucleic acid recognition abilities of both Cas13a and Cas12a, offering enhanced sensitivity compared to single Cas-based assays. #CRISPR #biosensor #miRNA #biomarker #diagnostics The Cas13a-12a amplification method has shown remarkable sensitivity, with a detection limit of 0.35 fM, significantly lower than that of the Cas13a-based assay alone. It also demonstrates high specificity, effectively distinguishing miRNA-155 from similar interfering miRNAs. The method has been successfully applied to quantify miRNA-155 expression levels in clinical samples from cancer patients, demonstrating its potential for clinical use in early disease diagnosis and identification of tumor patients. #precisionmedicine #personalizedmedicine

Conventional screening options for colorectal cancer (CRC) detection are mainly direct visualization and invasive methods, which must be performed in a clinical setting and may be linked to adverse effects for some patients. Non-invasive CRC diagnostic tests such are either too costly or less reliable than invasive ones. On the other hand, volatile organic compounds (VOCs) are potentially ideal non-invasive biomarkers for CRC detection and monitoring. This review presents the current state-of-the-art VOC-based CRC diagnostics, with a specific focus on recent advancements in biosensor design and application. #MDPIOpenAccess

At-home colorectal cancer screening promotes early detection. Did you know only 50% of Americans follow recommended screening schedules? Yet, when caught early, the 5-year survival rate jumps to 90%. Healthcare providers can make a difference. From innovative FIT tests to RNA biomarkers, at-home options are making screening more accessible than ever. Ready to boost screening rates? Check out our latest blog post to learn more: https://bit.ly/4fqf5py

Looking to improve trial performance in the HemeOnc setting? ✅Understand the Disease: Thoroughly comprehend the specific hematological cancer's pathology, clinical manifestations, and current treatment guidelines. This ensures an appropriate trial design. ✅Define the Disease Accurately: Precisely define disease terminology considering the unique characteristics of hematological cancers compared to solid tumors. This avoids confusion and ensures accurate enrollment. ✅Consider Biomarkers: Integrate biomarker identification into the trial design to select patients with specific genetic profiles for targeted therapies. This may significantly reduce the eligible patient pool and require broader screening. ✅Understand the Treatment Landscape: Be knowledgeable about the existing treatment options and clinical practices for the targeted hematological cancer. This helps design trials that address unmet needs and align with current practices. #heme #oncology #cancerawareness #cancerresearch #biotech

Did you know that the turnaround times (TATs) for oncology biomarker profiling can be as long as 25 days? This extended timeframe has a significant impact on patients' outcomes. To address this issue, we invite you to join our webinar on rapid molecular profiling, where we will discuss the importance of timely biomarker analysis and its role in optimizing patient outcomes. #thermofisheremp

Did you know that the turnaround times (TATs) for oncology biomarker profiling can be as long as 25 days? This extended timeframe has a significant impact on patients' outcomes. To address this issue, we invite you to join our webinar on rapid molecular profiling, where we will discuss the importance of timely biomarker analysis and its role in optimizing patient outcomes. #thermofisheremp

Did you know that the turnaround times (TATs) for oncology biomarker profiling can be as long as 25 days? This extended timeframe has a significant impact on patients' outcomes. To address this issue, we invite you to join our webinar on rapid molecular profiling, where we will discuss the importance of timely biomarker analysis and its role in optimizing patient outcomes. #thermofisheremp

Did you know that the turnaround times (TATs) for oncology biomarker profiling can be as long as 25 days? This extended timeframe has a significant impact on patients' outcomes. To address this issue, we invite you to join our webinar on rapid molecular profiling, where we will discuss the importance of timely biomarker analysis and its role in optimizing patient outcomes. #thermofisheremp

Did you know that the turnaround times (TATs) for oncology biomarker profiling can be as long as 25 days? This extended timeframe has a significant impact on patients' outcomes. To address this issue, we invite you to join our webinar on rapid molecular profiling, where we will discuss the importance of timely biomarker analysis and its role in optimizing patient outcomes. #thermofisheremp

Did you know that the turnaround times (TATs) for oncology biomarker profiling can be as long as 25 days? This extended timeframe has a significant impact on patients' outcomes. To address this issue, we invite you to join our webinar on rapid molecular profiling, where we will discuss the importance of timely biomarker analysis and its role in optimizing patient outcomes. #thermofisheremp